Manufacturing The strategic investments expanding CDMO capabilities for HPAPIs and ADCs Pharmaceutical TechnologyDemand for HPAPIs and ADCs is accelerating, prompting CDMOs to invest to strengthen manufacturing capabilities for oncology.Read full story pharminent April 29, 2026 (Last updated: April 29, 2026) Pharmaceutical Technology Demand for HPAPIs and ADCs is accelerating, prompting CDMOs to invest to strengthen manufacturing capabilities for oncology. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Novartis’ Q1 sales miss hints at industry’s utilisation of M&A remediesNext: Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact Related Stories Manufacturing FDA Warning Letter Hits Sanofi’s Genzyme Ireland Site pharminent July 8, 2026 Manufacturing Tanabe pens deal to sell plants to Towa in post-buyout pivot pharminent July 8, 2026 Manufacturing FDA Selects Seven for PreCheck Pilot to Advance Drug Manufacturing pharminent July 1, 2026
